Return to Listing

23 result(s) for

PI Name Protocol # Title
Rebecca Silbermann IRB00008820 Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Jeremy Cetnar IRB00011046 [NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Raymond Bergan STUDY00015588 Serial Measurements of Molecular and Architectural Responses to Therapy
Jeremy Cetnar STUDY00015597 A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versusPlacebo in Subjects with High Risk Invasive Urothelial Carcinoma
Jeremy Cetnar STUDY00015662 CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
Jeremy Cetnar STUDY00016230 A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Jacqueline Vuky STUDY00016702 A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors
Christopher Ryan STUDY00017027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
Jeremy Cetnar STUDY00017685 CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Christopher Ryan STUDY00018084 [NCI CIRB] S1609, "DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS”
Christopher Ryan STUDY00018121 A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Alexey Danilov STUDY00018655 A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination with PD-1 Antagonist Nivolumab in Patients with Transformed Chronic Lymphocytic Leukemia (Richter’s Transformation) or Non-Hodgkin Lymphoma
Skye Mayo STUDY00018937 A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
Jeremy Cetnar STUDY00019009 A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Jeremy Cetnar STUDY00019259 Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
Jeremy Cetnar STUDY00019301 Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Christopher Ryan STUDY00019661 [NCI CIRB] EA8143 (PROSPER): A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
Julie Graff STUDY00019782 [WIRB - IAA] A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Christopher Ryan STUDY00019991 [NCI CIRB] A031704 - PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Charles Lopez STUDY00020075 [NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Christopher Ryan STUDY00020148 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Christopher Ryan STUDY00020229 [NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Craig Okada STUDY00020485 [NCI CIRB] S1826 - A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080